



EPI benefits versus COVID–19 risks

HepB3 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children




EPI benefits versus COVID–19 risks

Hib3 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



EPI benefits versus COVID–19 risks

MCV1 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children




benefit–risk ratio



600  
400  
200

EPI benefits versus COVID–19 risks

PCV3 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



benefit–risk ratio



50  
40  
30  
20  
10


## EPI benefits versus COVID–19 risks

RCV1 / EPI suspension period: 6 months / vaccine impact: under 5–year–old children




RotaC / EPI suspension period: 6 months / vaccine impact: under 5-year-old children

RotaC / EPI suspension period: 6 months / vaccine impact: under 5-year-old children




EPI benefits versus COVID–19 risks

YFV / EPI suspension period: 6 months / vaccine impact: under 5–year–old children



EPI benefits versus COVID–19 risks

MenA / EPI suspension period: 6 months / vaccine impact: under 5–year–old children





## EPI benefits versus COVID–19 risks

HPVfem / EPI suspension period: 6 months / vaccine impact: under 5–year–old children

